Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics reported strong financial results for Q4 and FY 2022, with Q4 revenue of $103.1 million, up from $98.8 million in Q4 2021, and total FY revenue of $401.9 million, compared to $366.0 million in 2021. Q4 diluted net income per share was $0.14, down from $0.26 year-over-year. The company forecasts 2023 revenue between $430 million and $450 million. Corcept is advancing clinical trials for multiple cortisol modulators, with significant progress anticipated in treatments for Cushing's syndrome, ALS, and NASH. The NDA submission for relacorilant is expected in Q1 2024.
Corcept Therapeutics (NASDAQ: CORT) is set to release its fourth quarter and full-year 2022 financial results on February 28, 2023. The announcement will be accompanied by a corporate update and a conference call at 5:00 p.m. ET (2:00 p.m. PT). To participate, dial 877-407-8029 from the U.S. or +1-201-689-8029 internationally. A replay of the call will be accessible on the company’s website.
Corcept is known for its proprietary cortisol modulators, including its FDA-approved drug Korlym®, used to treat Cushing’s syndrome.
Corcept Therapeutics (NASDAQ: CORT) announced updates on its proprietary selective cortisol modulator, miricorilant, targeting antipsychotic-induced weight gain (AIWG) and non-alcoholic steatohepatitis (NASH). The trials for AIWG showed no reversal of weight gain, though miricorilant was effective in reducing liver fat in ongoing NASH studies. Promising results from pre-clinical and Phase 1 studies suggest potential further investigation into preventing AIWG. The company plans to conduct a Phase 2 trial next year for NASH.
Corcept Therapeutics (NASDAQ: CORT) announced a settlement with Hikma Pharmaceuticals regarding patent litigation for its medication, Korlym®, used for treating Cushing's syndrome. The agreement allows Hikma to market a generic version of Korlym starting October 1, 2034, facilitating Corcept's focus on business growth and development of new cortisol modulators. The settlement awaits court approval and is subject to review by the FTC and DOJ. Corcept continues its clinical trials for various conditions linked to cortisol modulation, maintaining a strong intellectual property portfolio.
Corcept Therapeutics (CORT) reported Q3 2022 revenue of $101.7 million, up from $96.1 million in Q3 2021. The company tightened its 2022 revenue guidance to $400 - $410 million. Net income increased to $34.6 million or $0.30 per share. However, revenue was impacted by reduced in-person physician interactions post-pandemic. Corcept is optimistic about ongoing clinical trials, particularly for treatments targeting Cushing's syndrome and ALS, with upcoming significant readouts expected.
Corcept Therapeutics (NASDAQ: CORT) will report its third-quarter financial results and provide a corporate update on November 3, 2022. A conference call is scheduled for 5:00 p.m. ET, where participants will need to register in advance. Corcept is known for its proprietary compounds that modulate cortisol effects, targeting numerous serious conditions, including Cushing’s syndrome and various cancers. The company’s drug, Korlym®, is FDA-approved for Cushing’s syndrome.
Corcept Therapeutics (NASDAQ: CORT) has initiated DAZALS, a Phase 2 trial evaluating its cortisol modulator, dazucorilant, for treating ALS (amyotrophic lateral sclerosis). The 198-patient, randomized, double-blind, placebo-controlled study aims to assess the drug's efficacy in improving ALS symptoms and safety. Dazucorilant has shown promising results in animal models, enhancing motor performance and reducing neuroinflammation. This partnership with TRICALS, an ALS academic consortium in Europe, highlights Corcept's commitment to addressing the unmet needs in ALS treatment.
Corcept Therapeutics (CORT) reported Q2 2022 revenue of $103.4 million, an increase from $91.6 million in Q2 2021. The company reiterated its 2022 revenue guidance of $400 - $430 million. Net income for the quarter was $27.4 million or $0.24 per share, up from $0.21 in the prior year. Cash and investments rose to $382.0 million, reflecting solid growth. Corcept continues to advance clinical trials for relacorilant, addressing conditions such as platinum-resistant ovarian cancer and Cushing’s syndrome, with completion of multiple Phase 2 trials expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and provide a corporate update on August 3, 2022, with a conference call at 5:00 p.m. ET. The company has a robust portfolio of proprietary compounds targeting cortisol modulation for severe disorders, including Cushing’s syndrome and cancers. They are also working on clinical trials for other conditions. The call will be accessible through registration, and a replay will be available on their website.
Corcept Therapeutics announced the initiation of the ROSELLA Phase 3 trial for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. The previous Phase 2 trial demonstrated improved progression-free survival, duration of response, and overall survival without increasing side effects. The pivotal trial aims to enroll 360 women and is critical as limited treatment options exist for this patient population. Success could establish relacorilant as a new standard of care.